

## ESOPHAGOGASTRIC DISEASE ORIENTED GROUP

CHELSEA HOTEL, TORONTO, ON  
ROOM: ROSSETTI  
SATURDAY MAY 4, 2019, 2:30 PM – 3:30 PM

CO-CHAIRS : DR. THIERRY ALCINDOR, DR. GAIL DARLING & DR. AAMER MAHMUD  
SENIOR INVESTIGATOR: DR. CHRIS O'CALLAGHAN

**CME Credits:**

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.*

**Learning Objectives:**

- To identify and address, through clinical and translational research, the disease burden associated with esophagogastric malignancies in Canada.
- To identify clinical trial research opportunities in esophagogastric malignancies within the Canadian Cancer Trials Group.
- To integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct as these relate to esophagogastric malignancies.
- To integrate and apply new clinical trial methodologies in esophagogastric malignancies in the Canadian Cancer Trials Group research agenda.
- To provide a learning and mentoring environment supportive to new investigators.

2:30 pm	Welcome	Dr. T. Alcindor Dr. G. Darling Dr. A. Mahmud
2:35 pm	POWERRANGER - Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma	Dr. G. Buduhan
2:45 pm	Concept: Neoadjuvant Immunotherapy in Esophageal Cancer	Dr. G. Darling
2:55 pm	GA.1 (TOP GEAR): A Randomized Phase III Trial of Preoperative Chemoradiotherapy versus Preoperative Chemotherapy for Resectable Gastric Cancer	Dr. R. Wong

3:00 pm	GA.3 (INTEGRATE II): A Randomized Phase 3 Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Oesophago-Gastric Cancer (AOGC)	Dr. T. Alcindor
3:05 pm	Concept: INTEGRATE III	Dr. T. Price
3:15 pm	Intergroup Task Force Update	Dr. T. Alcindor Dr. G. Darling Dr. A. Mahmud
3:30 pm	Meeting Adjourned	